Market Overview

Certara's D360 Version 10.5 Extends Platform's Ability to Optimize Discovery Research Across Therapeutic Modalities


Certara has increased D360's oligonucleotide research
capabilities, while continuing to enhance its visualization features,
workflows, and usability

Certara®, the global leader in model-informed drug development,
regulatory science, market access and real-world evidence services,
today announced the launch of D360 v10.5, the first in a series of
releases focused on delivering biologic-relevant tools together with
D360's world-class data access capabilities.

This latest release of Certara's D360 self-service data informatics
platform upgrades the efficiency and consistency of data-driven
biologics research workflows for drug discovery scientists, adds a new
multi-parameter scoring capability, and improves data analysis and
visualization across all modalities.

With the advent of recombinant DNA technology and biomanufacturing,
therapeutic discovery projects increasingly center on biologic
modalities, especially oligonucleotides. The worldwide biologic drugs
market is estimated to be valued at more than $200 billion, growing at a
rate of 10% per year.1 While informatics systems for
capturing biologics data are maturing, scientists often lack the tools
required to understand and prioritize these entities efficiently,
relying on manually-curated spreadsheets for crucial decision making.

"While many of our customers use D360 for biologics and small molecule
research already, this latest release delivers discovery tools that
significantly strengthen the platform's oligonucleotide capabilities and
workflows. We have also incorporated feedback from thousands of D360
users to fine-tune workflows and usability across modality types,
allowing scientists to focus on the data and science instead of the
software they are using," said David Lowis, DPhil, senior director of
D360 at Certara.

D360 v10.5's new discovery research capabilities for biologics include:

  • Oligonucleotide search by composition and similarity
  • Oligonucleotide sequence rendering and formatting
  • Oligonucleotide sequence filtering by composition and similarity
  • Searching, filtering and rendering of HELM (Hierarchical Editing
    Language for Macromolecules)

In addition, D360 v10.5 features modality-independent, flexible,
multi-parameter scoring that takes all relevant parameters into account
and balances them against each other so that the best candidates can be
identified quickly and consistently. Scientists can create, save, reuse,
and share multi-parameter scoring functions that assess an array of
multiple molecular properties to ensure efficacy, bioavailability and

Certara also continues to enhance D360's visualization features so that
scientists can easily understand data's meaning in a therapeutic
context. The ability to visualize trends and their relationship to the
compounds being tested allows more rapid understanding of structure
activity relationships leading to improved decisions on project

Employed by more than 5,000 scientists worldwide, D360 enables
researchers to cut dramatically the time required to access and analyze
data and gain new insights. Beyond the ability to ask and answer
questions in real time, D360 allows users to create virtual compounds to
analyze alongside those assays created in the laboratory.

To promote sharing of best practices and educate users about D360 v10.5,
Certara is holding its D360 User Group Meeting on Oct. 9 and 10 in
Dublin, Ireland. For more information, please contact



About Certara

Certara enables superior drug development and patient care
decision-making through model-informed drug development, regulatory
science, real-world evidence and knowledge integration. As a result, it
optimizes R&D productivity, commercial value and patient outcomes. Its
clients include hundreds of global biopharmaceutical companies, leading
academic institutions, and key regulatory agencies across 60 countries.
For more information, visit

View Comments and Join the Discussion!